Literature DB >> 3091275

Fc receptors on monocytes cause OKT3-treated lymphocytes to internalize T3 and to secrete IL-2.

E A Rinnooy Kan, S D Wright, K Welte, C Y Wang.   

Abstract

Monocytes cause OKT3-treated T cells to secrete IL-2 and to lose cell surface T3. We have studied the fate of the "lost" T3. Immunofluorescence microscopy on permeabilized cells showed that monocytes induce T cells to internalize T3. Furthermore, experiments with radioiodinated T cells showed that the internalized T3 was not degraded and exhibited an unaltered polypeptide composition for at least 16 hr. The role of Fc receptors in inducing internalization was also investigated. Fc receptors were depleted from monocytes by allowing the phagocytes to spread on immune complexes. Such depleted monocytes exhibit a fourfold reduction in their ability to promote both internalization of T3 and production of IL-2. A comparable reduction is seen if F(ab')2 fragments of OKT3 were employed in place of intact IgG. Furthermore, monocyte Fc receptors that have been blocked by heat-aggregated human IgG also show much reduced capability for induction of OKT3-mediated T-cell proliferation. We therefore conclude that Fc receptors bind to the Fc domain of OKT3 and thereby cause OKT3-treated T cells to internalize T3 and become activated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091275     DOI: 10.1016/0008-8749(86)90278-9

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  12 in total

1.  Major histocompatibility complex class II- fetal skin dendritic cells are potent accessory cells of polyclonal T-cell responses.

Authors:  A Elbe-Bürger; A M Mommaas; E E Prieschl; E Fiebiger; T Baumruker; G Stingl
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

2.  LFA-1-dependent OKT3-driven T cell clusters in common variable immunodeficiency.

Authors:  W Rudnicka; N English; J Farrant; M E North; A E Bryant; A J Edwards; A Stackpoole; A D Webster; B M Balfour
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

Review 3.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

4.  Effects of anti-CD3 monoclonal antibodies on functional activity of lymphocytes: studies in vivo and in vitro.

Authors:  K J Parlevliet; M E Chamuleau; S L Yong; M H Raasveld; I J ten Berge; P T Schellekens
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

5.  A correlative and quantitative imaging approach enabling characterization of primary cell-cell communication: Case of human CD4+ T cell-macrophage immunological synapses.

Authors:  Richard Kasprowicz; Emma Rand; Peter J O'Toole; Nathalie Signoret
Journal:  Sci Rep       Date:  2018-05-22       Impact factor: 4.379

6.  Specific inhibition of OKT3-driven T-cell mitogenesis by an anti HLA-class I monoclonal antibody.

Authors:  I Beckman; X Xiaoning; J Bradley
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

7.  Characterization of a surrogate murine antibody to model anti-human CD3 therapies.

Authors:  Fabien Dépis; Eric Hatterer; Romain Ballet; Bruno Daubeuf; Laura Cons; Sophie Glatt; Walter Reith; Marie Kosco-Vilbois; Yann Dean
Journal:  MAbs       Date:  2013-04-18       Impact factor: 5.857

8.  Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy.

Authors:  J A Smith; J Y Tso; M R Clark; M S Cole; J A Bluestone
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307

9.  A small number of anti-CD3 molecules on dendritic cells stimulate DNA synthesis in mouse T lymphocytes.

Authors:  N Romani; K Inaba; E Puré; M Crowley; M Witmer-Pack; R M Steinman
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

10.  Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells.

Authors:  R Goto; S You; M Zaitsu; L Chatenoud; K J Wood
Journal:  Am J Transplant       Date:  2013-06-10       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.